𝔖 Bobbio Scriptorium

✦ LIBER ✦

3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results

✍ Scribed by M. Rothenberg; M. Navarro; C. Butts; Y. Bang; J. Cox; R. Goel; S. Gollins; L. Siu; D. Cunningham

Book ID: 118625782
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 79 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70940-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EC3 COST-MINIMIZATION ANALYSIS OF CAPECI

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

✍ G Perrocheau; M Ducreux; M Hebbar; M Ychou; G Lledo; T Conroy; R Faroux; JY Doui 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

636 POSTER Initial safety findings from

636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 258 KB

599 ORAL Improved activity with irinotec

599 ORAL Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 262 KB

617 POSTER Initial safety findings from

617 POSTER Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB

FOXFIRE protocol: an open-label, randomi

FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer

✍ Susan J Dutton,Nicola Kenealy,Sharon B Love,Harpreet S Wasan… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 333 KB